secwatch / observer
8-K filed February 5, 2025, 6:59 PM ET CIK 0001061027
other material confidence high sentiment negative materiality 1.00

Viracta Therapeutics, Inc.: restructuring charge — Viracta Therapeutics terminates employees, wind down operations; all directors resign

Viracta Therapeutics, Inc.

item 2.05item 5.02item 8.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Rothera

President and Chief Executive Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Appointed

Craig R. Jalbert

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
Departed

Michael Faerm

Chief Financial Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed

Roger Pomerantz

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Appointed

Craig R. Jalbert

Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary
Viracta Therapeutics, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
Departed

Darrel P. Cohen

Chief Medical Officer
Viracta Therapeutics, Inc.
Effective
2025-02-05
Filed
February 5, 2025, 6:59 PM ET
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Departed

Thomas E. Darcy

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed

Mark Rothera

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed

Ivor Royston

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Departed

Flavia Borellini

Director
Viracta Therapeutics, Inc.
Effective
2025-02-05
Successor
Craig R. Jalbert
Filed
February 5, 2025, 6:59 PM ET
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Rothera departed as President and Chief Executive Officer at Viracta Therapeutics, Inc..

Action
ceased serving
Role
President and Chief Executive Officer
Exact text from the filing
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Craig R. Jalbert was appointed as Director at Viracta Therapeutics, Inc..

Action
appointed
Role
Director
Exact text from the filing
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Faerm departed as Chief Financial Officer at Viracta Therapeutics, Inc..

Action
ceased serving
Role
Chief Financial Officer
Exact text from the filing
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Roger Pomerantz resigned as Director at Viracta Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Craig R. Jalbert was appointed as Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary at Viracta Therapeutics, Inc..

Action
appointed
Role
Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary
Exact text from the filing
the Board appointed Craig R. Jalbert, age 63, as the Company's Chief Executive Officer, President, Chief Financial Officer, Treasurer and Corporate Secretary, and sole member of the Board.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Darrel P. Cohen departed as Chief Medical Officer at Viracta Therapeutics, Inc..

Action
ceased serving
Role
Chief Medical Officer
Exact text from the filing
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas E. Darcy resigned as Director at Viracta Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Mark Rothera resigned as Director at Viracta Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Ivor Royston resigned as Director at Viracta Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Flavia Borellini resigned as Director at Viracta Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Viracta Therapeutics, Inc. announced a restructuring with charges of approximately $0.1 million.

Type
restructuring
Charge
approximately $0.1 million
Exact text from the filing
The Company expects to incur one-time charges and cash expenditures associated with the workforce reduction of approximately $0.1 million, primarily related to employee wages and severance payments, benefits and related termination costs.
View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Source: SEC EDGAR
accession 0000950170-25-014630
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.